

Dr Manish Saxena



Nominee Election Year – 2010

Nominee Title & Institution - Clinical Co-Director, William Harvey Clinical Research Centre
Barts Health NHS Trust & Queen Mary University London

Nominee's Personal Statement –

I have been ESH Accredited HTN Specialist and an Academic at William Harvey Research Institute, Barts Health and Queen Mary University London for 20 yrs. In these years, have gained invaluable experience in hypertension. It has provided me great opportunities in research, pioneering novel devices and pharmacotherapies for hypertension and cardio-metabolic disease as part of big international collaborations. Currently, I am UK lead for commercial and NIHR funded programs in HTN such as RNAi, Natriuretic Peptide Receptor Agonist, Aldosterone Synthase Inhibitors, Non-Steroidal MRA, Renal denervation with endeavour to have better treatment options for hypertension.

As a Fellow and a long-standing member of BIHS for many years, I have been actively participating in BIHS activities. By applying for this role, I want to contribute more in promoting and delivering HTN and Cardiometabolic research across UK. Would be grateful for your support.

Nominated by – Prof. Sir Mark Caulfield, Vice Principal for Health Queen Mary University of London Faculty of Medicine and Dentistry, Director of the NIHR Barts Biomedical Research Centre

Supporting Statement –

I am delighted to nominate/support the nomination of Dr Manish Saxena to the Executive Committee of the British and Irish Hypertension Society (BIHS).

Dr Manish Saxena is a Cardiovascular physician and ESH Accredited Hypertension Specialist at Barts Health NHS Trust and Queen Mary University London, UK. He has been doing specialist hypertension for over 15 years. He is a Fellow and member of British and Irish Hypertension society. He is UK lead and National coordinator on studies pioneering development of novel devices and pharmaco-therapies for diagnosis and treatment of hypertension. These includes novel devices for blood pressure and heart rhythm monitoring using contact and contactless PPG

technologies. He has been Principal Investigator at Barts Health on BIHS studies validating new BP devices. He is UK lead for novel therapies for treatment of HTN, such as RNAi Zilebesiran, Natriuretic peptide receptor agonist and Aldosterone synthase inhibitors in HTN and is UK lead for device therapies in HTN such as renal denervation using ultrasound energy and chemical denervation.

He is passionate about optimising cardiometabolic risk factors in high-risk patients to improve outcomes and is UK lead on novel cardiometabolic therapies such as oral and injectable SiRNA PCSK9i, a CETP modulator, SiRNA for hyper-triglyceridemia, GLP1a in obesity/CVOT, Factor XIa inhibitor in Atrial Fibrillation and ASI with SGLT2i, NPR1a, K binders in CHF. Dr Saxena has been working closely with UK's Health Research Authority as a National Research Ethics Committee chair for 12 years and as Research Specialty Lead with National Institute of Health Research (NIHR), UK.

As part of BIHS Executive committee, he wants to promote and facilitate hypertension and cardiovascular clinical research at as many UK centers in secondary and primary care to address residual unmet need for blood pressure control. Dr Saxena has a unique position in the field of clinical hypertension research, leading and delivering commercial clinical trial activity and at a time when we need all the clinical academics we can get I am certain his skills and professionalism will be a great asset to the BIHS Executive Committee.

Supported by – Dr Pauline A. Swift, Consultant Nephrologist, Renal Services Associate Medical Director for Research & Education, Epsom and St. Helier University Hospitals NHS Trust, Trustee Blood Pressure UK , Executive Committee and Fellow BIHS

Supporting Statement –

I am delighted to endorse and support the nomination for Dr Manish Saxena for the position of Ordinary Member of the BIHS Executive

Dr Saxena holds a unique position in UK Hypertension research in that he has a leadership role in the NIHR for delivery of clinical trials in hypertension and cardiology, many of which are in partnership with industry. He has successfully led the delivery of these trials, by working in partnership with trialists across the UK.

He is part of a busy, world class hypertension team at Barts Health, to which I refer patients when in need of a second opinion.

He is a clinical academic who is inclusive, hard working and pragmatic and will be a great asset to the BIHS Executive

Seconded by - Dr Tim Doulton, Consultant Nephrologist, BIHS Accredited Hypertension Specialist, NIHR CRN: KSS Renal Disorders Specialty Group Co-Lead East Kent Hospitals University NHS Foundation Trust

Supporting Statement –

I have known Manish for a number of years, as a friendly and familiar face at BIHS meetings, through BIHS working party meetings and as a valued clinical colleague at the Bart's Hypertension Clinic to whom I have referred patients for second (or third) opinions. He has an impressive and growing profile as UK CI for CTIMPs/device trials of emerging therapies in the fields of hypertension and cardiovascular risk management, and I know that his knowledge and experience will bring great benefit to the activities of the BIHS Executive Committee. It is an honour to be asked to second Manish's nomination for this position, and I commend him to the membership for their support.

